IL309190A - Method and compositions for neuronal reprogramming - Google Patents
Method and compositions for neuronal reprogrammingInfo
- Publication number
- IL309190A IL309190A IL309190A IL30919023A IL309190A IL 309190 A IL309190 A IL 309190A IL 309190 A IL309190 A IL 309190A IL 30919023 A IL30919023 A IL 30919023A IL 309190 A IL309190 A IL 309190A
- Authority
- IL
- Israel
- Prior art keywords
- reprogramming
- preparations
- nerve cells
- nerve
- cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163208627P | 2021-06-09 | 2021-06-09 | |
| PCT/CA2022/050923 WO2022256933A1 (en) | 2021-06-09 | 2022-06-09 | Method and compositions for neuronal reprogramming |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL309190A true IL309190A (en) | 2024-02-01 |
Family
ID=84424544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL309190A IL309190A (en) | 2021-06-09 | 2022-06-09 | Method and compositions for neuronal reprogramming |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250282837A1 (https=) |
| EP (1) | EP4352085A4 (https=) |
| JP (1) | JP2024521401A (https=) |
| KR (1) | KR20240032021A (https=) |
| CN (1) | CN117881692A (https=) |
| AU (1) | AU2022288230A1 (https=) |
| BR (1) | BR112023025888A2 (https=) |
| CA (1) | CA3222129A1 (https=) |
| IL (1) | IL309190A (https=) |
| MX (1) | MX2023014769A (https=) |
| WO (1) | WO2022256933A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220084391A (ko) * | 2019-10-21 | 2022-06-21 | 에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) | 분기 형태들 합성 |
| CN115670390B (zh) * | 2022-12-30 | 2023-04-07 | 广东工业大学 | 一种帕金森病轴向症状严重程度表征方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014037527A1 (en) * | 2012-09-07 | 2014-03-13 | Cambridge Enterprise Limited | Maturation of mammalian cells by modulation of protein phosphorylation |
-
2022
- 2022-06-09 CA CA3222129A patent/CA3222129A1/en active Pending
- 2022-06-09 KR KR1020247000754A patent/KR20240032021A/ko active Pending
- 2022-06-09 AU AU2022288230A patent/AU2022288230A1/en active Pending
- 2022-06-09 MX MX2023014769A patent/MX2023014769A/es unknown
- 2022-06-09 CN CN202280051836.7A patent/CN117881692A/zh active Pending
- 2022-06-09 US US18/568,747 patent/US20250282837A1/en active Pending
- 2022-06-09 WO PCT/CA2022/050923 patent/WO2022256933A1/en not_active Ceased
- 2022-06-09 JP JP2023575711A patent/JP2024521401A/ja active Pending
- 2022-06-09 EP EP22819038.5A patent/EP4352085A4/en active Pending
- 2022-06-09 IL IL309190A patent/IL309190A/en unknown
- 2022-06-09 BR BR112023025888A patent/BR112023025888A2/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022288230A1 (en) | 2023-12-21 |
| MX2023014769A (es) | 2024-01-30 |
| EP4352085A4 (en) | 2025-07-23 |
| KR20240032021A (ko) | 2024-03-08 |
| CN117881692A (zh) | 2024-04-12 |
| US20250282837A1 (en) | 2025-09-11 |
| JP2024521401A (ja) | 2024-05-31 |
| EP4352085A1 (en) | 2024-04-17 |
| CA3222129A1 (en) | 2022-12-15 |
| WO2022256933A1 (en) | 2022-12-15 |
| BR112023025888A2 (pt) | 2024-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281109A (en) | Compositions and methods for enhancing triplex and nuclease-based gene editing | |
| IL285039A (en) | Compositions and methods for stimulating natural killer cells | |
| IL309190A (en) | Method and compositions for neuronal reprogramming | |
| EP3986449A4 (en) | In situ recruitment, reprogramming, and release of car-t cells | |
| EP3808833A4 (en) | CELL CULTURE SYSTEM AND CELL CULTURE PROCESS | |
| EP3808835A4 (en) | CELL CULTURE SYSTEM AND CELL CULTURE PROCESS | |
| EP4196133A4 (en) | METHODS AND COMPOSITIONS FOR STIMULATING GAMMA DELTA T CELLS | |
| DK3431507T3 (da) | Fusionsprotein omfattende nervevækstfaktor og fremstillingsfremgangsmåde og anvendelse deraf | |
| IL290297A (en) | Modified cytotoxic t cells and methods of use thereof | |
| IL284909A (en) | Interneuron-specific therapeutics for normalizing neuronal cell excitability and treating dravet syndrome | |
| EP4535437A4 (en) | SOLAR CELL AND ITS INTERCONNECTION PROCESS | |
| IL312485A (en) | T-cell modulatory multimeric polypeptides and methods of use thereof | |
| IL315149A (en) | System and method for treatment by electrophysiological stimulation | |
| EP3582716C0 (en) | METHOD, COMPUTER PROGRAM AND SIMULATION SYSTEM FOR AN OPTIMIZED IMPLANT SITE, AND OPTIMIZED IMPLANT SITE OBTAINED | |
| EP4269551A4 (en) | CELL CULTURE ELEMENT AND SURFACE MODIFICATION METHOD THEREOF | |
| EP4622047A4 (en) | BATTERY SYSTEM AND ITS CONTROL METHOD | |
| PL4149890T3 (pl) | Materiały czynne elektrody i sposób ich wytwarzania | |
| EP4289941A4 (en) | METHOD OF REPROGRAMMING A CELL | |
| IL312121A (en) | T cell manufacturing compositions and methods | |
| EP3842518A4 (en) | CELL CULTURE METHOD AND CELL CULTURE DEVICE | |
| IL315142A (en) | Methods and compositions for treating hearing loss | |
| PL3921372T3 (pl) | Hydrożel białkowy, jego sposób wytwarzania i zastosowanie | |
| EP4412543A4 (en) | CELLULAR GRAFTING IMPLANTATION DEVICES AND METHODS OF USE THEREOF | |
| EP3992277A4 (en) | CELL CULTURE CONTAINER AND CELL CULTURE APPARATUS | |
| EP3529396A4 (en) | ELECTROCHEMICAL CELL AND ITS PROCESS FOR USE |